Wai Conrad, CEO of Counterpart Health, sold 300,000 CLOVER HEALTH INVESTMENTS, CORP. /DE shares at $4.72 per share on Sep. 15, 2026. The transaction represented about 20.4% of the prior holding, while Conrad owned 1,170,056 shares afterward, giving investors a precise view of the remaining stake.
Key Highlights
- Wai Conrad sold 300,000 CLOVER HEALTH INVESTMENTS, CORP. /DE shares at $4.72 per share.
- The transaction was classified under code S, an open-market sale.
- Conrad owned 1,170,056 shares after the transaction, which represented about 20.4% of the prior holding.
Wai Conrad, CEO of Counterpart Health, sold 300,000 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (NASDAQ: CLOV) at $4.72 per share on Sep. 15, 2026. The transaction involved CLOVER Health stock and was classified with transaction code S. The reported price was $4.72 per share, and the transaction size was 300,000 shares.
Remaining CLOVER Health Holding
Following the sale, Wai Conrad owned 1,170,056 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE. The transaction represented about 20.4% of Conrad’s prior shares holding. The reported post-transaction balance covers the shares owned after the sale. Transaction code S denotes an open-market or private sale.
FAQs
Q: What did Wai Conrad sell in CLOVER Health?
A: Wai Conrad sold 300,000 CLOVER Health shares at $4.72 per share on Sep. 15, 2026. The transaction used code S, identifying an open-market sale.
Q: How many CLOVER Health shares did Wai Conrad retain?
A: Wai Conrad owned 1,170,056 CLOVER Health shares following the transaction. The reported balance reflects the holding after the 300,000-share sale.
Q: What percentage of Wai Conrad’s prior holding did the sale represent?
A: The CLOVER Health transaction represented about 20.4% of Wai Conrad’s prior shares holding. The sale involved 300,000 shares at $4.72 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.